1-8 of 8
Jorge M. Chaves
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 9873–9875.
https://doi.org/10.1182/blood-2022-162394
Published: 2022
Journal Articles

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Tae Min Kim, Dok Hyun Yoon, Ahmad H. Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, Seok Jin Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 3562.
https://doi.org/10.1182/blood-2021-149927
Published: 2021
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Christopher R Flowers, MD MS, Carlos Panizo, MD PhD, Iris Isufi, MD, Alex F. Herrera, MD, Craig Okada, MD PhD, Elizabeth H. Cull, MD, Bela Kis, MD, Jorge M. Chaves, MD, Nancy L. Bartlett, MD, Weiyun Ai, MD PhD, Luis de la Cruz-Merino, MD PhD, Locke J. Bryan, MD, Roch Houot, MD PhD, Kim Linton, MBChB PhD, Javier Briones, MD, Ian Chau, MD, Gottfried R. von Keudell, MD PhD, Hailing Lu, PhD, Frank J Hsu, MD, Ahmad S Halwani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2892.
https://doi.org/10.1182/blood-2018-99-117932
Published: 2018
Journal Articles

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Christopher Flowers, MD, Carlos Panizo, MD PhD, Iris Isufi, MD, Alex F. Herrera, MD, Craig Okada, MD PhD, Elizabeth H. Cull, MD, Bela Kis, MD, Jorge M. Chaves, MD, Nancy L. Bartlett, MD, Weiyun Ai, MD PhD, Luis de la Cruz-Merino, MD, Locke J. Bryan, MD, Roch Houot, MD PhD, Kim Linton, MBChB PhD, Javier Briones, MD, Ian Chau, MD, Gottfried R. von Keudell, MD PhD, Hailing Lu, PhD, Frank J Hsu, MD, Ahmad S. Halwani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2771.
https://doi.org/10.1182/blood.V130.Suppl_1.2771.2771
Published: 2017
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, William G Wierda, MD PhD, Anna Schuh, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Peter Martin, MD, Farrukh T. Awan, MD MS, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD, John M. Pagel, MD PhD, Jennifer A. Woyach, MD, Prista Charuworn, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Wayne M. Rothbaum, Min Hui Wang, PhD, Richard R. Furman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 498.
https://doi.org/10.1182/blood.V130.Suppl_1.498.498
Published: 2017
Journal Articles

The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile

John C. Byrd, MD, William Wierda, MD PhD, Jeffrey Jones, MD MPH, Susan O'Brien, MD, Jennifer R. Brown, MD PhD, Anna Schuh, MD PhD, Peter Hillmen, MB, ChB, PhD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Steve Devereux, MD, Jorge M. Chaves, MD, Jacqueline C. Barrientos, MD, Min Hui Wang, PhD, Jane Huang, MD, Todd Covey, Tasheda Navarro, Wayne Rothbaum, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Richard R. Furman, MD
Journal: Blood
Blood (2015) 126 (23): 831.
https://doi.org/10.1182/blood.V126.23.831.831
Published: 2015